Healthpeak Properties heads into its May 6 earnings call with options traders decidedly more defensive than they have been in months.
The clearest shift is in options positioning. The put/call ratio has climbed to 0.78, nearly 1.5 standard deviations above its 20-day average of 0.46 — a meaningful move toward downside protection in a name that spent most of April running a very call-heavy stance. That pivot is notable: through mid-April, the PCR was sitting around 0.21, close to its 52-week low. The jump to current levels in the past two weeks marks one of the sharpest sentiment reversals in recent history for the stock.
Short interest tells a more neutral story. At 4.4% of the free float, the borrow is not crowded by any measure. Short positions fell roughly 3.6% over the past week to around 30.6 million shares, trimming back from a spike that briefly pushed SI above 38 million shares on April 17. Borrow conditions remain loose — cost to borrow is just 0.46% and has eased about 9% over the past week, signalling no squeeze pressure in the lending market. Availability is ample. The stock itself has barely moved over the past month, up less than a tenth of a percent, though it recovered 2.9% on the week ahead of the print, closing at $16.51.
The analyst community has grown more cautious. Morgan Stanley's Richard Hill lowered his price target from $21 to $18 just last week — while holding his Overweight rating — a sign of conviction tempered by near-term concern. UBS initiated at Neutral with a $17 target in April. The broader trend has been consistent target-cutting across the Street, with the consensus mean now at $19.47, implying roughly 18% upside from current levels. Bears point to rising lab-tenant credit risk, weak leasing momentum in the life science segment, and a FFOPS growth trajectory that has been revised down sharply — to roughly flat through 2027. Bulls counter with a portfolio of ~700 properties, high pre-lease rates on new development, and mid-7% stabilised yields on $148 million in active projects. The EPS surprise factor score sits in the 90th percentile, meaning the company has a strong track record of beating estimates — a data point bulls are leaning on heading into the print.
Institutional flows add a quietly constructive note. Fuller & Thaler added nearly 4.8 million shares in the most recently reported quarter, and FMR added 6.8 million shares — two active managers making meaningful moves that suggest at least some conviction on the buy side beneath the index-heavy ownership structure. Insider activity, by contrast, has been entirely on the sell side — though all recent transactions carry the lowest significance score and are small enough to reflect routine compensation disposals rather than directional conviction.
The earnings report tests whether Healthpeak's lab occupancy trajectory and leasing pipeline can offer enough near-term visibility to narrow the gap between where the stock is and where most analysts still think it belongs.
See the live data behind this article on ORTEX.
Open DOC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
